Voriconazole
Antifungal drug with similar structure than fluconazole available for systemic, oral and intravenous use, and topically for ophthalmic purposes.
A latest update no published data on excretion in breast milk were found.
Pharmacokinetic data indicates that it may likely pass into the milk in amounts that could be significant.
Authorized use in children as young as 2 years of age. It has been used in 10-months-old infants.
Until more published data on this drug regarding breastfeeding is available, safer alternatives of better known drugs, should be preferable, especially during the neonatal period and in case of prematurity.
The small dose and poor absorption into plasma of most ophthalmic preparations makes it unlikely the pass of the drug into breast milk in significant amount.
Alternatives
- Fluconazole (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- βορικοναζόλη (Greek)
- فوريكونازول (Arabic)
- Вориконазол (Cyrillic)
- 伏立康唑 (Chinese)
- ボリコナゾール (Japanese)
- C16H14N5F3O (Molecular formula)
Drug trade names
References
- Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010Abstract
- Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010Abstract
- Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006Abstract